HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits

Executive Summary

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

You may also be interested in...



Perrigo Delivering Opill Sales Within A Month, Launches ‘Energize’ Efficiency Project Immediately

Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.

Pressure On Opill Price From Lawmakers, Health Advocates, Not From Marketplace Competition

Pressure from members of Congress and public and reproductive health advocacy groups will continue for making Opill’s price affordable to consumers from all income levels, but competition won’t affect the price for three years.

US Wellness Market People News: Herbalife, Bobbie Baby, Optimum Nutrition, Nutrabolt, More

“Gronk” motivates for Optimum Health; Osaka promotes paid paternal leave with Bobbie Baby; MidOcean changes CEOs at QualiTech; Nutrabolt expands revenue chief’s oversight; Gratziani climbs higher on Herbalife ladder; and Enzymedica adds Natural Group COO.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel